{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:03:02Z","timestamp":1793214182387,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier","isbn-type":[{"value":"9780323900874","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.acr.2022.03.007","type":"book-chapter","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T16:12:03Z","timestamp":1651335123000},"page":"1-27","source":"Crossref","is-referenced-by-count":91,"title":["An overview of chemotoxicity and radiation toxicity in cancer therapy"],"prefix":"10.1016","member":"78","reference":[{"issue":"7","key":"10.1016\/bs.acr.2022.03.007_bb0010","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14656566.2019.1582643","article-title":"Choosing the right pharmacotherapy for non-Hodgkin's lymphoma: Does one size fit all?","volume":"20","author":"Al Juhaishi","year":"2019","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.007_bb0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00001622-200203000-00012","article-title":"Cutaneous toxicities of cancer therapy","volume":"14","author":"Alley","year":"2002","journal-title":"Current Opinion in Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.007_bb0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cncr.27732","article-title":"Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer","volume":"119","author":"Argyriou","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.007_bb0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","article-title":"Cardiac toxicity of thoracic radiotherapy: Existing evidence and future directions","volume":"16","author":"Banfill","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/bs.acr.2022.03.007_bb0030","series-title":"Clinical pharmacy guide: Cancer drug treatment assessment and review","author":"BC Cancer","year":"2020"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.007_bb0035","first-page":"1999","article-title":"A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration","volume":"22","author":"Beijers","year":"2014","journal-title":"Support Care Cancer"},{"issue":"31","key":"10.1016\/bs.acr.2022.03.007_bb0040","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.007_bb0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccm.2004.05.006","article-title":"Drug-induced and iatrogenic infiltrative lung disease","volume":"25","author":"Camus","year":"2004","journal-title":"Clinics in Chest Medicine"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.007_bb0050","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: Expert panel opinion","volume":"56","author":"Coutre","year":"2015","journal-title":"Leukemia & Lymphoma"},{"issue":"24","key":"10.1016\/bs.acr.2022.03.007_bb0055","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1056\/NEJMc2002527","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.007_bb0060","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.21873\/anticanres.15396","article-title":"Radiation pneumonitis after volumetric modulated arc therapy for non-small cell lung cancer","volume":"41","author":"Fujiwara","year":"2021","journal-title":"Anticancer Research"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.007_bb0065","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12885-018-4185-0","article-title":"The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: A systematic review","volume":"18","author":"Gebremedhn","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.007_bb0070","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"18","key":"10.1016\/bs.acr.2022.03.007_bb0075","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.007_bb0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.007_bb0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/fon-2019-0844","article-title":"ALPINE: Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"16","author":"Hillmen","year":"2020","journal-title":"Future Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.007_bb0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaccao.2019.07.004","article-title":"Immune-checkpoint inhibitor-induced fulminant myocarditis and cardiogenic shock","volume":"1","author":"Itzhaki Ben Zadok","year":"2019","journal-title":"JACC CardioOncology"},{"key":"10.1016\/bs.acr.2022.03.007_bb0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.radonc.2020.07.051","article-title":"An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib","volume":"152","author":"Jia","year":"2020","journal-title":"Radiotherapy and Oncology"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.007_bb0100","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: A cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 1","key":"10.1016\/bs.acr.2022.03.007_bb0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, Oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"American Journal of Clinical Dermatology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.007_bb0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0025-6196(12)61616-4","article-title":"Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy","volume":"69","author":"Lee","year":"1994","journal-title":"Mayo Clinic Proceedings"},{"issue":"Suppl 2","key":"10.1016\/bs.acr.2022.03.007_bb0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/resp.13915","article-title":"Pulmonary toxicity of systemic lung cancer therapy","volume":"25","author":"Long","year":"2020","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.007_bb0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.007_bb0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: A review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"Journal of Nephrology"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.007_bb0130","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: When genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nature Reviews. Cancer"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.007_bb0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1006\/dbio.1997.8593","article-title":"Impaired lung branching morphogenesis in the absence of functional EGF receptor","volume":"186","author":"Miettinen","year":"1997","journal-title":"Developmental Biology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.007_bb0140","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.007_bb0145","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.007_bb0150","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.semradonc.2017.04.010","article-title":"Pelvic radiation and Normal tissue toxicity","volume":"27","author":"Nicholas","year":"2017","journal-title":"Seminars in Radiation Oncology"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.007_bb0155","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14740338.2016.1238067","article-title":"Incidence and implications of chemotherapy related hand-foot syndrome","volume":"15","author":"Nikolaou","year":"2016","journal-title":"Expert Opinion on Drug Safety"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.007_bb0160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.seminoncol.2005.11.004","article-title":"Dermatologic toxicity of chemotherapeutic agents","volume":"33","author":"Payne","year":"2006","journal-title":"Seminars in Oncology"},{"key":"10.1016\/bs.acr.2022.03.007_bb0165","article-title":"Prevention of oxaliplatin-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"12","author":"Peng","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.007_bb0170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/000155599750010382","article-title":"Exfoliative dermatitis after long-term methotrexate treatment of severe psoriasis","volume":"79","author":"Peters","year":"1999","journal-title":"Acta Dermato-Venereologica"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.007_bb0175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CAD.0000000000000032","article-title":"Life-threatening dermatologic adverse events in oncology","volume":"25","author":"Rosen","year":"2014","journal-title":"Anti-Cancer Drugs"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.007_bb0180","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/COC.0000000000000158","article-title":"Neurocognitive deficits after radiation therapy for brain malignancies","volume":"38","author":"Saad","year":"2015","journal-title":"American Journal of Clinical Oncology"},{"issue":"13","key":"10.1016\/bs.acr.2022.03.007_bb0185","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/bs.acr.2022.03.007_bb0190","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: A review","volume":"10","author":"Sara","year":"2018","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.007_bb0195","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1078155213502569","article-title":"A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide","volume":"20","author":"Shaaban","year":"2014","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.007_bb0200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/14737140.2017.1285231","article-title":"Minimizing toxicity in breast irradiation","volume":"17","author":"Shah","year":"2017","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.007_bb0205","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.semradonc.2017.04.008","article-title":"Management of Radiation Toxicity in head and neck cancers","volume":"27","author":"Siddiqui","year":"2017","journal-title":"Seminars in Radiation Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.007_bb0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1525-1470.1991.tb00867.x","article-title":"Discrete pigmentation after chemotherapy","volume":"8","author":"Singal","year":"1991","journal-title":"Pediatric Dermatology"},{"issue":"13","key":"10.1016\/bs.acr.2022.03.007_bb0215","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.007_bb0220","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.27654","volume":"132","author":"Stintzing","year":"2013","journal-title":"International Journal of Cancer"},{"key":"10.1016\/bs.acr.2022.03.007_bb0225","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.007_bb0230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1023\/A:1025480914273","article-title":"A phase II trial of pemetrexed in patients with metastatic renal cancer","volume":"21","author":"Thodtmann","year":"2003","journal-title":"Investigational New Drugs"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.007_bb0235","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13014-021-01899-y","article-title":"The impact of pelvic radiotherapy on the gut microbiome and its role in radiation-induced diarrhoea: A systematic review","volume":"16","author":"Wang","year":"2021","journal-title":"Radiation Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.007_bb0240","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/15548627.2017.1409405","article-title":"Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux","volume":"14","author":"Wang","year":"2018","journal-title":"Autophagy"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.007_bb0245","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41416-018-0300-x","article-title":"Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK","volume":"119","author":"Watson","year":"2018","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.acr.2022.03.007_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.lrr.2021.100275","article-title":"Role of antibody-based therapy in indolent non-Hodgkin's lymphoma","volume":"16","author":"Willard","year":"2021","journal-title":"Leukemia Research Reports"}],"container-title":["Advances in Cancer Research","Strategies to Mitigate the Toxicity of Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X22000409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X22000409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T20:10:33Z","timestamp":1753301433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X22000409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323900874"],"references-count":49,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2022.03.007","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}